Jessica Franzetti
Overview
Jessica Franzetti is an associate in Crowell’s New York office and a member of the firm’s Antitrust and Competition and White Collar and Regulatory Enforcement groups. Jessica counsels and represents clients in a wide range of regulatory enforcement, white collar criminal defense, and internal investigation matters. Jessica represents corporate and individual clients in criminal and civil antitrust investigations related to hiring practices, bid-rigging, and procurement fraud.
Career & Education
- Securities and Exchange Commission
Legal Intern, Division of Enforcement, 2020 - New York
Legal Intern, Special Investigations Unit, Office of the New York Attorney General, 2018
- Securities and Exchange Commission
- University of Delaware, B.A.
- Brooklyn Law School, J.D.
- New York
- U.S. District Court for the Southern District of New York
Jessica's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Publication | 08.12.25
Client Alert | 4 min read | 07.11.25
Representative Matters
- Represented a major corporation in the aerospace industry in investigations by the Department of Justice into hiring practices (no-poach/nonsolicitation).
- Represented a multinational corporation in an internal investigation into potential bid-rigging.
- Represented AT&T Inc. in its $1.175 billion sale of its Crunchyroll business to Sony.
- Represented a major veterinary services provider in a Federal Trade Commission merger investigation.
- Represented several clients in DOJ and FTC antitrust investigations.
Jessica's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Publication | 08.12.25
Client Alert | 4 min read | 07.11.25
Insights
- |
03.29.24
New York Law Journal
The Epic Trade Secret Saga Continues – Will the Supreme Court take the case?
|10.29.21
Crowell & Moring’s Trade Secrets Trends
Jessica's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Publication | 08.12.25
Client Alert | 4 min read | 07.11.25
